| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Advances in the systemic treatment of melanoma brain metastases
|
Glitza Oliva, I.C.
|
|
|
29 |
7 |
p. 1509-1520
|
article
|
| 2 |
A phase I dose-escalation and dose-expansion study of brontictuzumab in subjects with selected solid tumors
|
Ferrarotto, R.
|
|
|
29 |
7 |
p. 1561-1568
|
article
|
| 3 |
A phase II study of temsirolimus added to low-dose weekly carboplatin and paclitaxel for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)
|
Dunn, L.A.
|
|
|
29 |
7 |
p. 1606
|
article
|
| 4 |
Circulating tumour cell increase as a biomarker of disease progression in metastatic castration-resistant prostate cancer patients with low baseline CTC counts
|
Lorente, D.
|
|
|
29 |
7 |
p. 1554-1560
|
article
|
| 5 |
Editorial board
|
|
|
|
29 |
7 |
p. ii-iii
|
article
|
| 6 |
Hemophagocytic lymphohistiocytosis associated with dabrafenib and trametinib combination therapy following pembrolizumab administration for advanced melanoma
|
Sasaki, K.
|
|
|
29 |
7 |
p. 1602-1603
|
article
|
| 7 |
HER2 positive rates are enriched amongst colorectal cancer brain metastases: a study amongst 1920 consecutive patients
|
Tan, R.Y.C.
|
|
|
29 |
7 |
p. 1598-1599
|
article
|
| 8 |
Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab
|
Swain, S.M.
|
|
|
29 |
7 |
p. 1607
|
article
|
| 9 |
Neoadjuvant rectal score as individual-level surrogate for disease-free survival in rectal cancer in the CAO/ARO/AIO-04 randomized phase III trial
|
Fokas, E.
|
|
|
29 |
7 |
p. 1521-1527
|
article
|
| 10 |
Neoadjuvant score in locally advanced rectal cancer: integrating downstaging in risk assessment and looking for new valuable end points
|
Roselló, S.
|
|
|
29 |
7 |
p. 1493-1494
|
article
|
| 11 |
New formulation, new drug? The importance of assessing the safety of new supportive care formulations in oncology
|
Jordan, K.
|
|
|
29 |
7 |
p. 1494-1496
|
article
|
| 12 |
Phase III safety study of intravenous NEPA: a novel fixed antiemetic combination of fosnetupitant and palonosetron in patients receiving highly emetogenic chemotherapy
|
Schwartzberg, L.
|
|
|
29 |
7 |
p. 1535-1540
|
article
|
| 13 |
Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis
|
Poggio, F.
|
|
|
29 |
7 |
p. 1497-1508
|
article
|
| 14 |
Primary tumor sidedness and benefit from FOLFOXIRI plus bevacizumab as initial therapy for metastatic colorectal cancer. Retrospective analysis of the TRIBE trial by GONO
|
Cremolini, C.
|
|
|
29 |
7 |
p. 1528-1534
|
article
|
| 15 |
Radio-pharmaceuticals for cancer treatment: are they ready for prime time yet?
|
Turck, R.
|
|
|
29 |
7 |
p. 1594-1597
|
article
|
| 16 |
Randomized phase III study of docetaxel plus bavituximab in previously treated advanced non-squamous non-small-cell lung cancer
|
Gerber, D.E.
|
|
|
29 |
7 |
p. 1548-1553
|
article
|
| 17 |
Representation of obese participants in obesity-related cancer randomized trials
|
Pestine, E.
|
|
|
29 |
7 |
p. 1582-1587
|
article
|
| 18 |
Surveillance imaging with FDG-PET/CT in the post-operative follow-up of stage 3 melanoma
|
Lewin, J.
|
|
|
29 |
7 |
p. 1569-1574
|
article
|
| 19 |
Table of Contents
|
|
|
|
29 |
7 |
p. iv-v
|
article
|
| 20 |
Tailoring treatment of salivary duct carcinoma (SDC) by liquid biopsy: ARv7 expression in circulating tumor cells
|
Cappelletti, V.
|
|
|
29 |
7 |
p. 1599-1601
|
article
|
| 21 |
Targeting the fibroblast growth factor receptor 2 in gastric cancer: promise or pitfall?
|
Hierro, C.
|
|
|
29 |
7 |
p. 1605
|
article
|
| 22 |
T cells isolated from patients with checkpoint inhibitor-resistant melanoma are functional and can mediate tumor regression
|
Andersen, R.
|
|
|
29 |
7 |
p. 1575-1581
|
article
|
| 23 |
The hard road to patient-centered care: 3 or 6 months of adjuvant chemotherapy for patients with stage III colon cancer?
|
Trensz, P.
|
|
|
29 |
7 |
p. 1601
|
article
|
| 24 |
The importance of jointly analyzing treatment administration and toxicity associated with targeted therapies: a case study of regorafenib in soft tissue sarcoma patients
|
Longué, M.
|
|
|
29 |
7 |
p. 1588-1593
|
article
|
| 25 |
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer
|
Hortobagyi, G.N.
|
|
|
29 |
7 |
p. 1541-1547
|
article
|
| 26 |
Validation of a new prognostic model to easily predict outcome in renal cell carcinoma: the GRANT score applied to the ASSURE trial population
|
Buti, S.
|
|
|
29 |
7 |
p. 1604
|
article
|
Journal description